search
Back to results

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Primary Purpose

Solid Tumors

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Entrectinib
Entrectinib
Alectinib
Atezolizumab
Ipatasertib
Trastuzumab emtansine
Idasanutlin
Inavolisib
Belvarafenib
Pralsetinib
GDC-6036
Camonsertib
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumors

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy
  • Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Response Assessment in Neuro-Oncology (RANO) criteria, or International Neuroblastoma Response Criteria (INRC)
  • Performance status as follows: Participantss aged >= 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participantss aged 16 to < 18 years: Karnofsky score >= 50%; Participants aged < 16 years: Lansky score >= 50%
  • For participants aged >= 18 and <18 years: adequate hematologic and end-organ function
  • Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment
  • Adequate recovery from most recent systemic or local treatment for cancer
  • Life expectancy >= 8 weeks
  • Ability to comply with the study protocol, in the investigator's judgment
  • For female participants of childbearing potential: Negative serum pregnancy test <= 14 days prior to initiating study treatment; agreement to remain abstinent or use single or combined contraception methods that result in a failure rate of < 1% per year for the period defined in the cohort-specific inclusion criteria; and agreement to refrain from donating eggs during the same period
  • For male participants: Willingness to remain abstinent or use acceptable methods of contraception as defined in the cohort-specific inclusion criteria
  • In addition to the general inclusion criteria above, participants must meet all of the cohort-specific inclusion criteria for the respective cohort

Exclusion Criteria:

  • Current participation or enrollment in another therapeutic clinical trial
  • Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment
  • Whole brain radiotherapy within 14 days prior to start of study treatment
  • Stereotactic radiosurgery within 7 days prior to start of study treatment
  • Pregnant or breastfeeding, or intending to become pregnant during the study
  • History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study
  • Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
  • Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
  • History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy
  • In addition to the general exclusion criteria above, in order to be enrolled in a treatment cohort of the study, participants must not meet any of the cohort-specific exclusion criteria

Sites / Locations

  • Southern Cancer CenterRecruiting
  • Western Regional Medical Center at Cancer Treatment Centers of AmericaRecruiting
  • City of Hope National Medical Center
  • Kaiser Permanente Los Angeles; Clinic/Infusion -LA
  • USC Norris Cancer CenterRecruiting
  • Hoag Memorial HospitalRecruiting
  • UC Davis Comprehensive Cancer CenterRecruiting
  • University of California at San Francisco
  • Sarcoma Oncology CenterRecruiting
  • Children's Hospital Colorado; Center For Cancer/Blood DisorderRecruiting
  • Christiana Care Health Srvcs; Helen F Graham Can Center
  • University of Florida
  • Miami Cancer Institute of Baptist Health, Inc.Recruiting
  • Ocala Oncology CenterRecruiting
  • University Cancer & Blood Center, LLC; ResearchRecruiting
  • St. AlphonsusRecruiting
  • Midwestern Regional Med Center
  • Horizon Oncology Research, Inc.
  • New England Cancer Specialists
  • Maryland Hematology & Oncology. P.A.Recruiting
  • St. Joseph Mercy HospitalRecruiting
  • Henry Ford Health SystemRecruiting
  • University of Minnesota
  • Metro-Minnesota Community Oncology Research ConsortiumRecruiting
  • Washington University
  • St. Vincent Frontier Cancer CenterRecruiting
  • Comprehensive Cancer Centers of Nevada - Eastern Avenue
  • Dartmouth Hitchcock Medical CenterRecruiting
  • Rutgers Cancer Institute of New JerseyRecruiting
  • University of New Mexico; Comprehensive Cancer CenterRecruiting
  • Montefiore Einstein Center for Cancer CareRecruiting
  • Eastchester Center for Cancer Care
  • New York Cancer and Blood Specialists - Setauket Medical Oncology
  • National Translational Research Group
  • Icahn School of Medicine at Mount SinaiRecruiting
  • Memorial Sloan Kettering Cancer Center
  • Levine Cancer Institute
  • Barrett Cancer Center
  • Oncology Hematology Care IncRecruiting
  • Providence Portland Medical Center
  • Consultants in Medical Oncology and HematologyRecruiting
  • Alliance Cancer SpecialistsRecruiting
  • The Children's Hospital of PhiladelphiaRecruiting
  • Cancer Treatment Centers of America; Eastern Regional Medical Center
  • PRISMA Health - Greenville
  • The West Clinic; West Cancer CenterRecruiting
  • St. Jude Children'S Research HospitalRecruiting
  • Texas Onc-Central Austin CA CtRecruiting
  • Mary Crowley Medical Research CenterRecruiting
  • Texas Oncology - Baylor Charles A. Sammons Cancer CenterRecruiting
  • Cook Childrens Medical CenterRecruiting
  • The University of Texas MD Anderson Cancer CenterRecruiting
  • Texas Oncology- Northeast TexasRecruiting
  • Virginia Cancer Specialists - LeesburgRecruiting
  • Northwest Medical Specialties, PLLC; Research DepartmentRecruiting
  • Froedtert and The Medical College of WisconsinRecruiting
  • Kinghorn Cancer Centre; St Vincents HospitalRecruiting
  • Sydney Children's HospitalRecruiting
  • Royal Darwin Hospital; Alan Walker Cancer CentreRecruiting
  • Princess Alexandra HospitalRecruiting
  • Peter MacCallum Cancer Centre; Medical Oncology
  • Royal Children's HospitalRecruiting
  • Cliniques Universitaires St-LucRecruiting
  • GHdC Site Notre DameRecruiting
  • UZ Antwerpen
  • UZ GentRecruiting
  • UZ Leuven Gasthuisberg
  • Hospital Moinhos de VentoRecruiting
  • Hospital Sírio-Libanês
  • Hospital Sírio-LibanêsRecruiting
  • Hospital A. C. Camargo; OncologiaRecruiting
  • Clínica Onco Star - Rede D'OrRecruiting
  • BC Cancer ? Vancouver
  • London Health Sciences Centre · Victoria Hospital; Department of MedicineRecruiting
  • The Ottawa Hospital - General CampusRecruiting
  • The Hospital for Sick ChildrenRecruiting
  • Princess Margaret Cancer CenterRecruiting
  • McGill University Health CenterRecruiting
  • Beijing Children's Hospital, Capital Medical University; Oncological Surgery DepartmentRecruiting
  • Beijing Cancer HospitalRecruiting
  • The First Hospital of Jilin UniversityRecruiting
  • Jilin Cancer HospitalRecruiting
  • West China Hospital - Sichuan UniversityRecruiting
  • Zhongshan Hospital Fudan UnvierstiyRecruiting
  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of MedicineRecruiting
  • Shanghai East Hospital
  • Tianjin Cancer HospitalRecruiting
  • First Affiliated Hospital of Medical College of Xi'an Jiaotong UniversityRecruiting
  • Aarhus Universitetshospital; KræftafdelingenRecruiting
  • Rigshospitalet; Onkologisk KlinikRecruiting
  • Institut Bergonie; OncologieRecruiting
  • Centre Oscar Lambret; Service de Pediatrie
  • CENTRE LEON BERARD; Département d?Hématologie et d?Oncologie
  • Hopital de la TimoneRecruiting
  • Institut Universitaire du Cancer de Toulouse-Oncopole
  • Institut de Cancerologie Gustave-Roussy (IGR)
  • Uniklinik EssenRecruiting
  • Universitätsklinikum Freiburg Medizinische Klinik Innere Medizin I
  • Georg-August-Uniklinik ; Zentrum Innere Medizin Abt. Hämatologie & OnkologieRecruiting
  • Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik IIRecruiting
  • Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und HepatologieRecruiting
  • SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm.Recruiting
  • Praxis für Hämatologie, Onkologie und PalliativmedizinRecruiting
  • Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik IIIRecruiting
  • Universtitätsklinikum Ulm; Klinik für Innere Medizin IIIRecruiting
  • Uniklinikum, Comprehensive Cancer Center Mainfranken; Interdisziplinäres Studienzentrum mit ECTURecruiting
  • Hong Kong Children's HospitalRecruiting
  • Prince of Wales Hospital; Department of Clinical OnocologyRecruiting
  • Rambam Health Care Campus; OncologyRecruiting
  • Hadassah University Hospital - Ein Kerem
  • Rabin MC; Davidof Center - Oncology InstituteRecruiting
  • Sheba Medical CenterRecruiting
  • Sourasky / Ichilov Hospital; Dept. of OncologyRecruiting
  • Istituto Nazionale Tumori Fondazione G. PascaleRecruiting
  • Ospedale Pediatrico Bambino Gesù - IRCCS; Dipartimento di Onco-Ematologia PediatricaRecruiting
  • Policlinico Universitario Agostino Gemelli IRCCS; UOS Fase 1
  • Asst Degli Spedali Civili Di Brescia
  • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1Recruiting
  • Istituto Nazionale Tumori di Milano; S.C. Oncologia PediatricaRecruiting
  • Dipartimento di Scienze Pediatriche Adolescenza; Osp. Infantile Regina MargheritaRecruiting
  • Azienda Ospedaliera Meyer; Centro di Eccellenza di Oncologia ed Ematologia PediatricaRecruiting
  • Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia OncologicaRecruiting
  • National Cancer Center Hospital East
  • Kindai University Hospital
  • National Cancer Center Hospital
  • Seoul National University Bundang Hospital
  • Seoul National University Hospital- Adult SiteRecruiting
  • Seoul National University Hospital- Pediatric SiteRecruiting
  • Severance Hospital, Yonsei University Health SystemRecruiting
  • Asan Medical Center
  • Samsung Medical Center- Adult Site
  • Samsung Medical Center- Pediatric SiteRecruiting
  • Prinses Maxima Centrum
  • Auckland City Hospital, Cancer and Blood ResearchRecruiting
  • Christchurch Hospital; Dept of Oncology
  • Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
  • Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki PiersRecruiting
  • IPO do Porto; Servico de Oncologia Medica
  • PanOncology Trials; Hospital Oncológico, Puerto Rico Medical CenterRecruiting
  • National University Hospital; National University Cancer Institute, Singapore (NCIS)Recruiting
  • National Cancer Centre; Medical Oncology
  • Hospital Sant Joan De DeuRecruiting
  • Hospital Univ Vall d'Hebron; Servicio de OncologiaRecruiting
  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona
  • Hospital Infantil Universitario Nino JesusRecruiting
  • Clinica Universidad de Navarra Madrid; Servicio de OncologíaRecruiting
  • START Madrid-FJD, Hospital Fundacion Jimenez Diaz
  • Hospital Universitario 12 de Octubre; Servicio de Oncologia
  • Hospital Universitario La Paz; Servicio de OncologiaRecruiting
  • START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
  • Hospital Universitario la Fe; Servicio de OncologiaRecruiting
  • Universitätsspital Basel (USB)
  • Ospedale Regionale di Bellinzona Medizin Onkologie
  • Inselspital, Klinik und Poliklinik für Medizinische Onkologie
  • Unversitätsspital Zürich
  • National Cheng Kung University Hospital; OncologyRecruiting
  • Taipei Veterans General Hospital; Department of OncologyRecruiting
  • Chang Gung Memorial Hospital-Linkou; Dept of OncologyRecruiting
  • National Taiwan University Hospital; Oncology
  • Beatson West of Scotland Cancer CentreRecruiting
  • University College London HospitalRecruiting
  • Royal Manchester Children?s HospitalRecruiting
  • The Christie NHS Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm 13

Arm 14

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Cohort A: ROS1 Fusion-positive tumors (excluding NSCLC)

Cohort B: NTRK1/2/3 fusion-positive tumors

Cohort C: ALK fusion-positive tumors (excluding NSCLC)

Cohort D: TMB-high tumors

Cohort E: AKT1/2/3 mutant-positive tumors

Cohort F: HER2 mutant-positive tumors

Cohort G: MDM2-amplified, TP53 wild-type tumors

Cohort H: PIK3CA multiple mutant-positive tumors

Cohort I: BRAF class II mutant or fusion-positive tumors

Cohort J: BRAF class III mutant-positive tumors

Cohort K: RET fusion-positive tumors (excluding NSCLC)

Cohort L: KRAS G12C-positive tumors (excluding NSCLC and CRC)

Cohort M: ATM Loss of Function tumors

Cohort N: SETD2 Loss of Function tumors

Arm Description

Participants with metastatic or advanced solid tumors, with the exception of NSCLC will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) >/= 1.51 squaremeter (m2). The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.

Participants with metastatic or advanced solid tumors will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA >/= 1.51 m2. The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.

Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg orally twice a day (BID), taken with food, in repeated 28-day cycles.

Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged >/= 18 years, and 15 mg/kg (maximum 1200 mg) for participants aged < 18 years on Day 1 of each 21-day cycle. Note: Cohort D has been closed for enrollment

Participants with metastatic or advanced solid tumors will receive ipatasertib orally once daily (QD) at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants <35 kg, 300 mg for participants >/= 35 and <45 kg, 400 mg for those >/=45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. Note: Cohort E has been closed for enrollment

Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days. Note: Cohort F has been closed for enrollment

Participants with metastatic or advanced solid tumors will receive idasanutlin at a dose of 250 mg orally QD on Days 1-5 of each 28-day cycle. Note: Cohort G has been closed for enrollment

Participants with metastatic or advanced solid tumors will receive GDC-0077 QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles.

Participants with BRAF class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort I has been closed for enrollment

Participants with BRAF class III mutant-positive tumors(adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.

Participants with RET fusion-positive tumors will self-administer Pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and < 18 years of age. A treatment cycle consists of 4 weeks (28 days).

Participants with KRAS G12C-positive tumors will self-administer GDC-6036 orally at home (except on clinic days).

Participants with ATM Loss of Function tumors will self-administer Camonsertib orally at home (except on clinic days).

Participants with SETD2 Loss of Function tumors will self-administer Camonsertib orally at home (except on clinic days).

Outcomes

Primary Outcome Measures

All Cohorts: Independent Review Committee (IRC)-assessed objective response rate (ORR) based on confirmed objective response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
Confirmed objective response indicates >/= 4 weeks after initial documentation of response

Secondary Outcome Measures

All Cohorts: IRC-assessed duration of response (DOR) per RECIST v1.1
All Cohorts: IRC-assessed clinical benefit rate (CBR) per RECIST v1.1
All Cohorts: IRC-assessed progression free survival (PFS) per RECIST v1.1
All Cohorts: Investigator (INV)-assessed ORR per RECIST v1.1
All Cohorts: INV-assessed DOR per RECIST v1.1
All Cohorts: INV-assessed CBR per RECIST v1.1
All Cohorts: INV-assessed PFS per RECIST v1.1
All Cohorts: IRC- and INV-assessed time to central nervous system (CNS) progression per RECIST v1.1
All Cohorts: Overall Survival (OS)
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-ORR per Response Assessment in Neuro-Oncology (RANO)
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-DOR per RANO
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-CBR per RANO
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-PFS per RANO
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-ORR per RANO
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-DOR per RANO
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-CBR per RANO
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-PFS per RANO
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: IRC-assessed ORR per International Neuroblastoma Response Criteria (INRC)
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: KIRC-assessed DOR per INRC
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: IRC-assessed CBR per INRC
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: IRC-assessed PFS per INRC
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: INV-assessed ORR per INRC
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: INV-assessed DOR per INRC
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: INV-assessed CBR per INRC
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: INV-assessed PFS per INRC
All Cohorts: IRC-assessed ORR per RECIST v1.1 in participants with alteration/biomarker-positive circulating tumor DNA (ctDNA) by blood-based next-generation sequencing (NGS) assay
All Cohorts: IRC-assessed DOR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
All Cohorts: IRC-assessed CBR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
All Cohorts: IRC-assessed PFS per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
All Cohorts: INV-assessed ORR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
All Cohorts: INV-assessed DOR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
All Cohorts: INV-assessed CBR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
All Cohorts: INV-assessed PFS per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
Cohorts A, B, C, D, I, J, K: IRC-assessed intracranial (IC)-ORR per RECIST v1.1
Cohorts A, B, C, D, I, J, K: IRC-assessed IC-DOR per RECIST v1.1
Cohorts A, B, C, D, I, J, K: IRC-assessed IC-CBR per RECIST v1.1
Cohorts A, B, C, D, I, J, K: IRC-assessed IC-PFS rate per RECIST v1.1
Cohorts A, B, C, D, I, J, K: INV-assessed IC-ORR per RECIST v1.1
Cohorts A, B, C, D, I, J, K: INV-assessed IC-DOR per RECIST v1.1
Cohorts A, B, C, D, I, J, K: INV-assessed IC-CBR per RECIST v1.1
Cohorts A, B, C, D, I, J, K: INV-assessed IC-PFS rate per RECIST v1.1
All Cohorts: Percentage of participants with confirmed deterioration as assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)
The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points.
All Cohorts: Change from Baseline in the EORTC-QLQ-C30 total score
All Cohorts: Percentage of participants with a clinical meaningful change on the Global Health Status, Physical Functioning, and Role Functioning scores from the EORTC QLQ-C30
All Cohorts: Time to confirmed symptom onset or worsening from tumor-related symptom scores from the EORTC QLQ-C30 and EORTC Item Library
The EORTC Item library includes stand-alone symptoms scales and an overall assessment of treatment bother to provide additional information not currently captured in the EORTC QLQ-C30. The scales use the same rating scale and recall period of previous week as the symptom scales in the EORTC QLQ-C30.
All Cohorts: Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Adverse event severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE v5.0.)
Cohorts A, B: Plasma concentration of entrectinib at specified timepoints
Cohort C: Plasma concentration of alectinib at specified timepoints
Cohort D: Plasma concentration of atezolizumab at specified timepoints
Cohort E: Plasma concentration of ipatasertib at specified timepoints
Cohort F: Serum concentration of trastuzumab emtansine at specified timepoints
Cohort G: Plasma concentration of idasanutlin at specified timepoint
Cohort H: Plasma concentration of GDC-0077 at specified timepoints
Cohort L: Plasma concentration of GDC-6036 at specified timepoints
Cohort M: Plasma concentration of Camonsertib at specified timepoints
Cohort N: Plasma concentration of Camonsertib at specified timepoints
Cohorts D, F: Percentage of participants with anti-drug antibodies (ADA)

Full Information

First Posted
October 11, 2020
Last Updated
October 18, 2023
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT04589845
Brief Title
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Official Title
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 18, 2021 (Actual)
Primary Completion Date
September 25, 2032 (Anticipated)
Study Completion Date
September 25, 2032 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
920 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort A: ROS1 Fusion-positive tumors (excluding NSCLC)
Arm Type
Experimental
Arm Description
Participants with metastatic or advanced solid tumors, with the exception of NSCLC will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) >/= 1.51 squaremeter (m2). The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.
Arm Title
Cohort B: NTRK1/2/3 fusion-positive tumors
Arm Type
Experimental
Arm Description
Participants with metastatic or advanced solid tumors will receive entrectinib once daily in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA >/= 1.51 m2. The total dose of daily entrectinib administration for pediatric participants with BSA<1.51 m2 will be lower.
Arm Title
Cohort C: ALK fusion-positive tumors (excluding NSCLC)
Arm Type
Experimental
Arm Description
Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg orally twice a day (BID), taken with food, in repeated 28-day cycles.
Arm Title
Cohort D: TMB-high tumors
Arm Type
Experimental
Arm Description
Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged >/= 18 years, and 15 mg/kg (maximum 1200 mg) for participants aged < 18 years on Day 1 of each 21-day cycle. Note: Cohort D has been closed for enrollment
Arm Title
Cohort E: AKT1/2/3 mutant-positive tumors
Arm Type
Experimental
Arm Description
Participants with metastatic or advanced solid tumors will receive ipatasertib orally once daily (QD) at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants <35 kg, 300 mg for participants >/= 35 and <45 kg, 400 mg for those >/=45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. Note: Cohort E has been closed for enrollment
Arm Title
Cohort F: HER2 mutant-positive tumors
Arm Type
Experimental
Arm Description
Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days. Note: Cohort F has been closed for enrollment
Arm Title
Cohort G: MDM2-amplified, TP53 wild-type tumors
Arm Type
Experimental
Arm Description
Participants with metastatic or advanced solid tumors will receive idasanutlin at a dose of 250 mg orally QD on Days 1-5 of each 28-day cycle. Note: Cohort G has been closed for enrollment
Arm Title
Cohort H: PIK3CA multiple mutant-positive tumors
Arm Type
Experimental
Arm Description
Participants with metastatic or advanced solid tumors will receive GDC-0077 QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles.
Arm Title
Cohort I: BRAF class II mutant or fusion-positive tumors
Arm Type
Experimental
Arm Description
Participants with BRAF class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort I has been closed for enrollment
Arm Title
Cohort J: BRAF class III mutant-positive tumors
Arm Type
Experimental
Arm Description
Participants with BRAF class III mutant-positive tumors(adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib by mouth (PO) BID (twice a day) with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
Arm Title
Cohort K: RET fusion-positive tumors (excluding NSCLC)
Arm Type
Experimental
Arm Description
Participants with RET fusion-positive tumors will self-administer Pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and < 18 years of age. A treatment cycle consists of 4 weeks (28 days).
Arm Title
Cohort L: KRAS G12C-positive tumors (excluding NSCLC and CRC)
Arm Type
Experimental
Arm Description
Participants with KRAS G12C-positive tumors will self-administer GDC-6036 orally at home (except on clinic days).
Arm Title
Cohort M: ATM Loss of Function tumors
Arm Type
Experimental
Arm Description
Participants with ATM Loss of Function tumors will self-administer Camonsertib orally at home (except on clinic days).
Arm Title
Cohort N: SETD2 Loss of Function tumors
Arm Type
Experimental
Arm Description
Participants with SETD2 Loss of Function tumors will self-administer Camonsertib orally at home (except on clinic days).
Intervention Type
Drug
Intervention Name(s)
Entrectinib
Other Intervention Name(s)
Rozlytrek
Intervention Description
Adults and pediatric participants with a BSA >/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA < 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).
Intervention Type
Drug
Intervention Name(s)
Entrectinib
Other Intervention Name(s)
Rozlytrek
Intervention Description
Adults and pediatric participants with a BSA >/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA < 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).
Intervention Type
Drug
Intervention Name(s)
Alectinib
Other Intervention Name(s)
Alecensa
Intervention Description
Alectinib will be administered orally BID (twice a day) with food at a dosage of 600 mg (four 150-mg capsules).
Intervention Type
Drug
Intervention Name(s)
Atezolizumab
Other Intervention Name(s)
Tecentriq
Intervention Description
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged >/=18 years, and 15 mg/kg (maximum 1200 mg) for participants aged <18 years on Day 1 of each 21-day cycle.
Intervention Type
Drug
Intervention Name(s)
Ipatasertib
Intervention Description
For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants < 35 kg, 300 mg for participants >/= 35 and < 45 kg, 400 mg for those >/= 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
Intervention Type
Drug
Intervention Name(s)
Trastuzumab emtansine
Other Intervention Name(s)
Kadcyla
Intervention Description
Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
Intervention Type
Drug
Intervention Name(s)
Idasanutlin
Intervention Description
Idasanutlin will be administered at 250 mg QD (daily) PO for Days 1-5 of each 28-day cycle. Idasanutlin may be given without regard to meals and water can be given as often as necessary or desired. The daily doses should be administered 10-14 hours apart. Note: Cohort G has been closed for enrollment.
Intervention Type
Drug
Intervention Name(s)
Inavolisib
Other Intervention Name(s)
GDC-0077
Intervention Description
GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
Intervention Type
Drug
Intervention Name(s)
Belvarafenib
Intervention Description
Belvarafenib will be administered at a dose 400 mg (PO) BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
Intervention Type
Drug
Intervention Name(s)
Pralsetinib
Other Intervention Name(s)
Gavreto (US)
Intervention Description
Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and < 18 years of age. A treatment cycle consists of 4 weeks (28 days).
Intervention Type
Drug
Intervention Name(s)
GDC-6036
Intervention Description
GDC-6036 will be self-administered by patients orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric patients. A treatment cycle consists of 3 weeks (21 days).
Intervention Type
Drug
Intervention Name(s)
Camonsertib
Intervention Description
Camonsertib will be self-administered by patients orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
Primary Outcome Measure Information:
Title
All Cohorts: Independent Review Committee (IRC)-assessed objective response rate (ORR) based on confirmed objective response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
Description
Confirmed objective response indicates >/= 4 weeks after initial documentation of response
Time Frame
Approximately up to 12 years
Secondary Outcome Measure Information:
Title
All Cohorts: IRC-assessed duration of response (DOR) per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
All Cohorts: IRC-assessed clinical benefit rate (CBR) per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
All Cohorts: IRC-assessed progression free survival (PFS) per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
All Cohorts: Investigator (INV)-assessed ORR per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
All Cohorts: INV-assessed DOR per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
All Cohorts: INV-assessed CBR per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
All Cohorts: INV-assessed PFS per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
All Cohorts: IRC- and INV-assessed time to central nervous system (CNS) progression per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
All Cohorts: Overall Survival (OS)
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-ORR per Response Assessment in Neuro-Oncology (RANO)
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-DOR per RANO
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-CBR per RANO
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-PFS per RANO
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-ORR per RANO
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-DOR per RANO
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-CBR per RANO
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: INV-assessed CNS-PFS per RANO
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: IRC-assessed ORR per International Neuroblastoma Response Criteria (INRC)
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: KIRC-assessed DOR per INRC
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: IRC-assessed CBR per INRC
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: IRC-assessed PFS per INRC
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: INV-assessed ORR per INRC
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: INV-assessed DOR per INRC
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: INV-assessed CBR per INRC
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, E, F, G, H, I, J, K, L, M, N: INV-assessed PFS per INRC
Time Frame
Approximately up to 12 years
Title
All Cohorts: IRC-assessed ORR per RECIST v1.1 in participants with alteration/biomarker-positive circulating tumor DNA (ctDNA) by blood-based next-generation sequencing (NGS) assay
Time Frame
Approximately up to 12 years
Title
All Cohorts: IRC-assessed DOR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
Time Frame
Approximately up to 12 years
Title
All Cohorts: IRC-assessed CBR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
Time Frame
Approximately up to 12 years
Title
All Cohorts: IRC-assessed PFS per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
Time Frame
Approximately up to 12 years
Title
All Cohorts: INV-assessed ORR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
Time Frame
Approximately up to 12 years
Title
All Cohorts: INV-assessed DOR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
Time Frame
Approximately up to 12 years
Title
All Cohorts: INV-assessed CBR per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
Time Frame
Approximately up to 12 years
Title
All Cohorts: INV-assessed PFS per RECIST v1.1 in participants with alteration/biomarker-positive ctDNA by blood-based NGS assay
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: IRC-assessed intracranial (IC)-ORR per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: IRC-assessed IC-DOR per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: IRC-assessed IC-CBR per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: IRC-assessed IC-PFS rate per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: INV-assessed IC-ORR per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: INV-assessed IC-DOR per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: INV-assessed IC-CBR per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
Cohorts A, B, C, D, I, J, K: INV-assessed IC-PFS rate per RECIST v1.1
Time Frame
Approximately up to 12 years
Title
All Cohorts: Percentage of participants with confirmed deterioration as assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)
Description
The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points.
Time Frame
Approximately up to 12 years
Title
All Cohorts: Change from Baseline in the EORTC-QLQ-C30 total score
Time Frame
Approximately up to 12 years
Title
All Cohorts: Percentage of participants with a clinical meaningful change on the Global Health Status, Physical Functioning, and Role Functioning scores from the EORTC QLQ-C30
Time Frame
Approximately up to 12 years
Title
All Cohorts: Time to confirmed symptom onset or worsening from tumor-related symptom scores from the EORTC QLQ-C30 and EORTC Item Library
Description
The EORTC Item library includes stand-alone symptoms scales and an overall assessment of treatment bother to provide additional information not currently captured in the EORTC QLQ-C30. The scales use the same rating scale and recall period of previous week as the symptom scales in the EORTC QLQ-C30.
Time Frame
Approximately up to 12 years
Title
All Cohorts: Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Description
Adverse event severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE v5.0.)
Time Frame
Approximately up to 12 years
Title
Cohorts A, B: Plasma concentration of entrectinib at specified timepoints
Time Frame
Day 1 of Cycle 1-6 and Day 1 of every other Cycle going forward (one Cycle=28 days)
Title
Cohort C: Plasma concentration of alectinib at specified timepoints
Time Frame
Cycle 1, Day 1 and Day 15; Day 1 of Cycle 2-6, and Day 1 of every other Cycle going forward (one Cycle=28 days)
Title
Cohort D: Plasma concentration of atezolizumab at specified timepoints
Time Frame
Day 1 of Cycle 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, and every even Cycles thereafter (one Cycle=21 days)
Title
Cohort E: Plasma concentration of ipatasertib at specified timepoints
Time Frame
Cycle 1, Day 1 and 15; Cycle 2, Day 1; Cycle 3, Day 15; Cycle 4, Day 1, and every even Cycle thereafter (one Cycle=28 days)
Title
Cohort F: Serum concentration of trastuzumab emtansine at specified timepoints
Time Frame
Cycle 1, Day 1; Cycle 2, Day 1; Cycle 4, Day 1; Cycle 6, Day 1, and every even Cycle thereafter (one Cycle=21 days)
Title
Cohort G: Plasma concentration of idasanutlin at specified timepoint
Time Frame
Cycle 1, Day 1, 2, 5, 8; Cycle 2, Day 1, 2, 5; Cycle 3, Day 2, 5; Cycle 4, Day 1, and every other Cycle going forward (one Cycle=28 days)
Title
Cohort H: Plasma concentration of GDC-0077 at specified timepoints
Time Frame
Cycle 1, Day 1, 8 (+/-1 day), 15 (+/-1 day); Cycle 2, Day 1 (+/-1 day); Day 1 of Cycle 4, and every other even Cycle going forward (one Cycle=28 days)
Title
Cohort L: Plasma concentration of GDC-6036 at specified timepoints
Time Frame
Cycle 1: Day 1, 15; Cycles 2-5, Day 1, Cycle 7, Day 1 and every other cycle until post 1-year of treatment (Day of Cycles 7, 9, 11) (Cycle=21 days))
Title
Cohort M: Plasma concentration of Camonsertib at specified timepoints
Time Frame
Cycle 1, Day 1, 2, 8; Cycle 2-4, Day 1; Cycle 5, Day 1, and every odd cycle until post 1-year of treatment (Cycles 7, 9, 11, and 13) (Cycle=21 days))
Title
Cohort N: Plasma concentration of Camonsertib at specified timepoints
Time Frame
Cycle 1, Day 1, 2, 8; Cycle 2-4, Day 1; Cycle 5, Day 1, and every odd cycle until post 1-year of treatment (Cycles 7, 9, 11, and 13) (Cycle=21 days))
Title
Cohorts D, F: Percentage of participants with anti-drug antibodies (ADA)
Time Frame
Cohort D: Day 1 of Cycle 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, and every even Cycles thereafter (one Cycle=21 days); Cohort F: Cycle 1, Day 1; Cycle 2, Day 1; Cycle 4, Day 1; Cycle 6, Day 1, and every even Cycle thereafter (one Cycle=21 days)

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Response Assessment in Neuro-Oncology (RANO) criteria, or International Neuroblastoma Response Criteria (INRC) Performance status as follows: Participantss aged >= 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participantss aged 16 to < 18 years: Karnofsky score >= 50%; Participants aged < 16 years: Lansky score >= 50% For participants aged >= 18 and <18 years: adequate hematologic and end-organ function Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment Adequate recovery from most recent systemic or local treatment for cancer Life expectancy >= 8 weeks Ability to comply with the study protocol, in the investigator's judgment For female participants of childbearing potential: Negative serum pregnancy test <= 14 days prior to initiating study treatment; agreement to remain abstinent or use single or combined contraception methods that result in a failure rate of < 1% per year for the period defined in the cohort-specific inclusion criteria; and agreement to refrain from donating eggs during the same period For male participants: Willingness to remain abstinent or use acceptable methods of contraception as defined in the cohort-specific inclusion criteria In addition to the general inclusion criteria above, participants must meet all of the cohort-specific inclusion criteria for the respective cohort Exclusion Criteria: Current participation or enrollment in another therapeutic clinical trial Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment Whole brain radiotherapy within 14 days prior to start of study treatment Stereotactic radiosurgery within 7 days prior to start of study treatment Pregnant or breastfeeding, or intending to become pregnant during the study History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy In addition to the general exclusion criteria above, in order to be enrolled in a treatment cohort of the study, participants must not meet any of the cohort-specific exclusion criteria
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Reference Study ID Number: BO41932 https://forpatients.roche.com/
Phone
888-662-6728 (U.S. and Canada)
Email
Global-Roche-Genentech-Trials@gene.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
Southern Cancer Center
City
Daphne
State/Province
Alabama
ZIP/Postal Code
36526
Country
United States
Individual Site Status
Recruiting
Facility Name
Western Regional Medical Center at Cancer Treatment Centers of America
City
Goodyear
State/Province
Arizona
ZIP/Postal Code
85338
Country
United States
Individual Site Status
Recruiting
Facility Name
City of Hope National Medical Center
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Completed
Facility Name
Kaiser Permanente Los Angeles; Clinic/Infusion -LA
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
USC Norris Cancer Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Recruiting
Facility Name
Hoag Memorial Hospital
City
Newport Beach
State/Province
California
ZIP/Postal Code
92658
Country
United States
Individual Site Status
Recruiting
Facility Name
UC Davis Comprehensive Cancer Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Individual Site Status
Recruiting
Facility Name
University of California at San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Individual Site Status
Completed
Facility Name
Sarcoma Oncology Center
City
Santa Monica
State/Province
California
ZIP/Postal Code
90403
Country
United States
Individual Site Status
Recruiting
Facility Name
Children's Hospital Colorado; Center For Cancer/Blood Disorder
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Name
Christiana Care Health Srvcs; Helen F Graham Can Center
City
Newark
State/Province
Delaware
ZIP/Postal Code
19713
Country
United States
Individual Site Status
Completed
Facility Name
University of Florida
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32607
Country
United States
Individual Site Status
Withdrawn
Facility Name
Miami Cancer Institute of Baptist Health, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Individual Site Status
Recruiting
Facility Name
Ocala Oncology Center
City
Ocala
State/Province
Florida
ZIP/Postal Code
34471
Country
United States
Individual Site Status
Recruiting
Facility Name
University Cancer & Blood Center, LLC; Research
City
Athens
State/Province
Georgia
ZIP/Postal Code
30607
Country
United States
Individual Site Status
Recruiting
Facility Name
St. Alphonsus
City
Boise
State/Province
Idaho
ZIP/Postal Code
83706
Country
United States
Individual Site Status
Recruiting
Facility Name
Midwestern Regional Med Center
City
Zion
State/Province
Illinois
ZIP/Postal Code
60099
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Horizon Oncology Research, Inc.
City
Lafayette
State/Province
Indiana
ZIP/Postal Code
47905
Country
United States
Individual Site Status
Completed
Facility Name
New England Cancer Specialists
City
Scarborough
State/Province
Maine
ZIP/Postal Code
04074
Country
United States
Individual Site Status
Withdrawn
Facility Name
Maryland Hematology & Oncology. P.A.
City
Silver Spring
State/Province
Maryland
ZIP/Postal Code
20904
Country
United States
Individual Site Status
Recruiting
Facility Name
St. Joseph Mercy Hospital
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48106
Country
United States
Individual Site Status
Recruiting
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Individual Site Status
Withdrawn
Facility Name
Metro-Minnesota Community Oncology Research Consortium
City
Saint Louis Park
State/Province
Minnesota
ZIP/Postal Code
55416
Country
United States
Individual Site Status
Recruiting
Facility Name
Washington University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63128
Country
United States
Individual Site Status
Withdrawn
Facility Name
St. Vincent Frontier Cancer Center
City
Billings
State/Province
Montana
ZIP/Postal Code
59102
Country
United States
Individual Site Status
Recruiting
Facility Name
Comprehensive Cancer Centers of Nevada - Eastern Avenue
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89169
Country
United States
Individual Site Status
Withdrawn
Facility Name
Dartmouth Hitchcock Medical Center
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03756
Country
United States
Individual Site Status
Recruiting
Facility Name
Rutgers Cancer Institute of New Jersey
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08901
Country
United States
Individual Site Status
Recruiting
Facility Name
University of New Mexico; Comprehensive Cancer Center
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87131
Country
United States
Individual Site Status
Recruiting
Facility Name
Montefiore Einstein Center for Cancer Care
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Individual Site Status
Recruiting
Facility Name
Eastchester Center for Cancer Care
City
Bronx
State/Province
New York
ZIP/Postal Code
10469
Country
United States
Individual Site Status
Withdrawn
Facility Name
New York Cancer and Blood Specialists - Setauket Medical Oncology
City
East Setauket
State/Province
New York
ZIP/Postal Code
11733
Country
United States
Individual Site Status
Withdrawn
Facility Name
National Translational Research Group
City
New York
State/Province
New York
ZIP/Postal Code
10028
Country
United States
Individual Site Status
Withdrawn
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
11101
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Levine Cancer Institute
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Individual Site Status
Withdrawn
Facility Name
Barrett Cancer Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Completed
Facility Name
Oncology Hematology Care Inc
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Individual Site Status
Recruiting
Facility Name
Providence Portland Medical Center
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Individual Site Status
Completed
Facility Name
Consultants in Medical Oncology and Hematology
City
Broomall
State/Province
Pennsylvania
ZIP/Postal Code
19008
Country
United States
Individual Site Status
Recruiting
Facility Name
Alliance Cancer Specialists
City
Horsham
State/Province
Pennsylvania
ZIP/Postal Code
19044
Country
United States
Individual Site Status
Recruiting
Facility Name
The Children's Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Name
Cancer Treatment Centers of America; Eastern Regional Medical Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19124
Country
United States
Individual Site Status
Completed
Facility Name
PRISMA Health - Greenville
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29605
Country
United States
Individual Site Status
Withdrawn
Facility Name
The West Clinic; West Cancer Center
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Individual Site Status
Recruiting
Facility Name
St. Jude Children'S Research Hospital
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38105
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Onc-Central Austin CA Ct
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Individual Site Status
Recruiting
Facility Name
Mary Crowley Medical Research Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Oncology - Baylor Charles A. Sammons Cancer Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Individual Site Status
Recruiting
Facility Name
Cook Childrens Medical Center
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-4009
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Oncology- Northeast Texas
City
Tyler
State/Province
Texas
ZIP/Postal Code
75702
Country
United States
Individual Site Status
Recruiting
Facility Name
Virginia Cancer Specialists - Leesburg
City
Leesburg
State/Province
Virginia
ZIP/Postal Code
20176
Country
United States
Individual Site Status
Recruiting
Facility Name
Northwest Medical Specialties, PLLC; Research Department
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Individual Site Status
Recruiting
Facility Name
Froedtert and The Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Individual Site Status
Recruiting
Facility Name
Kinghorn Cancer Centre; St Vincents Hospital
City
Darlinghurst
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Individual Site Status
Recruiting
Facility Name
Sydney Children's Hospital
City
Randwick
State/Province
New South Wales
ZIP/Postal Code
2031
Country
Australia
Individual Site Status
Recruiting
Facility Name
Royal Darwin Hospital; Alan Walker Cancer Centre
City
Tiwi
State/Province
Northern Territory
ZIP/Postal Code
0810
Country
Australia
Individual Site Status
Recruiting
Facility Name
Princess Alexandra Hospital
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Individual Site Status
Recruiting
Facility Name
Peter MacCallum Cancer Centre; Medical Oncology
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3000
Country
Australia
Individual Site Status
Active, not recruiting
Facility Name
Royal Children's Hospital
City
Parkville
State/Province
Victoria
ZIP/Postal Code
3052
Country
Australia
Individual Site Status
Recruiting
Facility Name
Cliniques Universitaires St-Luc
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Name
GHdC Site Notre Dame
City
Charleroi
ZIP/Postal Code
6000
Country
Belgium
Individual Site Status
Recruiting
Facility Name
UZ Antwerpen
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Individual Site Status
Active, not recruiting
Facility Name
UZ Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Name
UZ Leuven Gasthuisberg
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Active, not recruiting
Facility Name
Hospital Moinhos de Vento
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90035-000
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hospital Sírio-Libanês
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
01308-050
Country
Brazil
Individual Site Status
Withdrawn
Facility Name
Hospital Sírio-Libanês
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
01308-050
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Hospital A. C. Camargo; Oncologia
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
01509-010
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Clínica Onco Star - Rede D'Or
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
04543-000
Country
Brazil
Individual Site Status
Recruiting
Facility Name
BC Cancer ? Vancouver
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E6
Country
Canada
Individual Site Status
Active, not recruiting
Facility Name
London Health Sciences Centre · Victoria Hospital; Department of Medicine
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5W9
Country
Canada
Individual Site Status
Recruiting
Facility Name
The Ottawa Hospital - General Campus
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Individual Site Status
Recruiting
Facility Name
The Hospital for Sick Children
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X8
Country
Canada
Individual Site Status
Recruiting
Facility Name
Princess Margaret Cancer Center
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Name
McGill University Health Center
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Individual Site Status
Recruiting
Facility Name
Beijing Children's Hospital, Capital Medical University; Oncological Surgery Department
City
Beijing City
ZIP/Postal Code
100032
Country
China
Individual Site Status
Recruiting
Facility Name
Beijing Cancer Hospital
City
Beijing
ZIP/Postal Code
100142
Country
China
Individual Site Status
Recruiting
Facility Name
The First Hospital of Jilin University
City
Changchun City
ZIP/Postal Code
130021
Country
China
Individual Site Status
Recruiting
Facility Name
Jilin Cancer Hospital
City
Changchun
ZIP/Postal Code
132013
Country
China
Individual Site Status
Recruiting
Facility Name
West China Hospital - Sichuan University
City
Chengdu City
ZIP/Postal Code
610047
Country
China
Individual Site Status
Recruiting
Facility Name
Zhongshan Hospital Fudan Unvierstiy
City
Shanghai City
ZIP/Postal Code
200032
Country
China
Individual Site Status
Recruiting
Facility Name
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
City
Shanghai
ZIP/Postal Code
200092
Country
China
Individual Site Status
Recruiting
Facility Name
Shanghai East Hospital
City
Shanghai
Country
China
Individual Site Status
Completed
Facility Name
Tianjin Cancer Hospital
City
Tianjin
ZIP/Postal Code
300060
Country
China
Individual Site Status
Recruiting
Facility Name
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
City
Xi'an
ZIP/Postal Code
710061
Country
China
Individual Site Status
Recruiting
Facility Name
Aarhus Universitetshospital; Kræftafdelingen
City
Aarhus N
ZIP/Postal Code
8200
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Rigshospitalet; Onkologisk Klinik
City
København Ø
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Institut Bergonie; Oncologie
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Individual Site Status
Recruiting
Facility Name
Centre Oscar Lambret; Service de Pediatrie
City
Lille
ZIP/Postal Code
59020
Country
France
Individual Site Status
Active, not recruiting
Facility Name
CENTRE LEON BERARD; Département d?Hématologie et d?Oncologie
City
Lyon
ZIP/Postal Code
69373
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hopital de la Timone
City
Marseille
ZIP/Postal Code
13005
Country
France
Individual Site Status
Recruiting
Facility Name
Institut Universitaire du Cancer de Toulouse-Oncopole
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Institut de Cancerologie Gustave-Roussy (IGR)
City
Villejuif
ZIP/Postal Code
94805
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Uniklinik Essen
City
Essen
ZIP/Postal Code
45122
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum Freiburg Medizinische Klinik Innere Medizin I
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Georg-August-Uniklinik ; Zentrum Innere Medizin Abt. Hämatologie & Onkologie
City
Göttingen
ZIP/Postal Code
37075
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Individual Site Status
Recruiting
Facility Name
Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und Hepatologie
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Individual Site Status
Recruiting
Facility Name
SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm.
City
Heilbronn
ZIP/Postal Code
74078
Country
Germany
Individual Site Status
Recruiting
Facility Name
Praxis für Hämatologie, Onkologie und Palliativmedizin
City
Mönchengladbach
ZIP/Postal Code
41066
Country
Germany
Individual Site Status
Recruiting
Facility Name
Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III
City
München
ZIP/Postal Code
81377
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universtitätsklinikum Ulm; Klinik für Innere Medizin III
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Individual Site Status
Recruiting
Facility Name
Uniklinikum, Comprehensive Cancer Center Mainfranken; Interdisziplinäres Studienzentrum mit ECTU
City
Würzburg
ZIP/Postal Code
97078
Country
Germany
Individual Site Status
Recruiting
Facility Name
Hong Kong Children's Hospital
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Name
Prince of Wales Hospital; Department of Clinical Onocology
City
Shatin
Country
Hong Kong
Individual Site Status
Recruiting
Facility Name
Rambam Health Care Campus; Oncology
City
Haifa
ZIP/Postal Code
3109601
Country
Israel
Individual Site Status
Recruiting
Facility Name
Hadassah University Hospital - Ein Kerem
City
Jerusalem
ZIP/Postal Code
9112001
Country
Israel
Individual Site Status
Active, not recruiting
Facility Name
Rabin MC; Davidof Center - Oncology Institute
City
Petach Tikva
ZIP/Postal Code
4941492
Country
Israel
Individual Site Status
Recruiting
Facility Name
Sheba Medical Center
City
Ramat Gan
ZIP/Postal Code
5262100
Country
Israel
Individual Site Status
Recruiting
Facility Name
Sourasky / Ichilov Hospital; Dept. of Oncology
City
Tel Aviv
ZIP/Postal Code
6423906
Country
Israel
Individual Site Status
Recruiting
Facility Name
Istituto Nazionale Tumori Fondazione G. Pascale
City
Napoli
State/Province
Campania
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Name
Ospedale Pediatrico Bambino Gesù - IRCCS; Dipartimento di Onco-Ematologia Pediatrica
City
Roma
State/Province
Lazio
ZIP/Postal Code
00165
Country
Italy
Individual Site Status
Recruiting
Facility Name
Policlinico Universitario Agostino Gemelli IRCCS; UOS Fase 1
City
Roma
State/Province
Lazio
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Asst Degli Spedali Civili Di Brescia
City
Brescia
State/Province
Lombardia
ZIP/Postal Code
25123
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Recruiting
Facility Name
Istituto Nazionale Tumori di Milano; S.C. Oncologia Pediatrica
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Recruiting
Facility Name
Dipartimento di Scienze Pediatriche Adolescenza; Osp. Infantile Regina Margherita
City
Torino
State/Province
Piemonte
ZIP/Postal Code
10126
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliera Meyer; Centro di Eccellenza di Oncologia ed Ematologia Pediatrica
City
Firenze
State/Province
Toscana
ZIP/Postal Code
50139
Country
Italy
Individual Site Status
Recruiting
Facility Name
Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
City
Siena
State/Province
Toscana
ZIP/Postal Code
53100
Country
Italy
Individual Site Status
Recruiting
Facility Name
National Cancer Center Hospital East
City
Chiba
ZIP/Postal Code
277-8577
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Kindai University Hospital
City
Osaka
ZIP/Postal Code
589-8511
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
National Cancer Center Hospital
City
Tokyo
ZIP/Postal Code
104-0045
Country
Japan
Individual Site Status
Active, not recruiting
Facility Name
Seoul National University Bundang Hospital
City
Seongnam-si
ZIP/Postal Code
463-707
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Seoul National University Hospital- Adult Site
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Seoul National University Hospital- Pediatric Site
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Severance Hospital, Yonsei University Health System
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Samsung Medical Center- Adult Site
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Active, not recruiting
Facility Name
Samsung Medical Center- Pediatric Site
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Prinses Maxima Centrum
City
Utrecht
ZIP/Postal Code
3584 CS
Country
Netherlands
Individual Site Status
Withdrawn
Facility Name
Auckland City Hospital, Cancer and Blood Research
City
Auckland
ZIP/Postal Code
1023
Country
New Zealand
Individual Site Status
Recruiting
Facility Name
Christchurch Hospital; Dept of Oncology
City
Christchurch
Country
New Zealand
Individual Site Status
Withdrawn
Facility Name
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
City
Gdansk
ZIP/Postal Code
80-214
Country
Poland
Individual Site Status
Active, not recruiting
Facility Name
Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers
City
Warszawa
ZIP/Postal Code
02-781
Country
Poland
Individual Site Status
Recruiting
Facility Name
IPO do Porto; Servico de Oncologia Medica
City
Porto
ZIP/Postal Code
4200-072
Country
Portugal
Individual Site Status
Active, not recruiting
Facility Name
PanOncology Trials; Hospital Oncológico, Puerto Rico Medical Center
City
San Juan
ZIP/Postal Code
00935
Country
Puerto Rico
Individual Site Status
Recruiting
Facility Name
National University Hospital; National University Cancer Institute, Singapore (NCIS)
City
Singapore
ZIP/Postal Code
119228
Country
Singapore
Individual Site Status
Recruiting
Facility Name
National Cancer Centre; Medical Oncology
City
Singapore
ZIP/Postal Code
168583
Country
Singapore
Individual Site Status
Active, not recruiting
Facility Name
Hospital Sant Joan De Deu
City
Esplugues De Llobregas
State/Province
Barcelona
ZIP/Postal Code
08950
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Univ Vall d'Hebron; Servicio de Oncologia
City
Sant Andreu de La Barca
State/Province
Barcelona
ZIP/Postal Code
08740
Country
Spain
Individual Site Status
Recruiting
Facility Name
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hospital Infantil Universitario Nino Jesus
City
Madrid
ZIP/Postal Code
28009
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinica Universidad de Navarra Madrid; Servicio de Oncología
City
Madrid
ZIP/Postal Code
28027
Country
Spain
Individual Site Status
Recruiting
Facility Name
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hospital Universitario 12 de Octubre; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hospital Universitario La Paz; Servicio de Oncologia
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Recruiting
Facility Name
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Individual Site Status
Active, not recruiting
Facility Name
Hospital Universitario la Fe; Servicio de Oncologia
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Name
Universitätsspital Basel (USB)
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Withdrawn
Facility Name
Ospedale Regionale di Bellinzona Medizin Onkologie
City
Bellinzona
ZIP/Postal Code
6500
Country
Switzerland
Individual Site Status
Withdrawn
Facility Name
Inselspital, Klinik und Poliklinik für Medizinische Onkologie
City
Bern
ZIP/Postal Code
3012
Country
Switzerland
Individual Site Status
Active, not recruiting
Facility Name
Unversitätsspital Zürich
City
Zürich
ZIP/Postal Code
8091
Country
Switzerland
Individual Site Status
Withdrawn
Facility Name
National Cheng Kung University Hospital; Oncology
City
Tainan
ZIP/Postal Code
00704
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Taipei Veterans General Hospital; Department of Oncology
City
Taipei City
ZIP/Postal Code
112201
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Chang Gung Memorial Hospital-Linkou; Dept of Oncology
City
Taoyuan County
ZIP/Postal Code
333
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
National Taiwan University Hospital; Oncology
City
Zhongzheng Dist.
ZIP/Postal Code
10048
Country
Taiwan
Individual Site Status
Active, not recruiting
Facility Name
Beatson West of Scotland Cancer Centre
City
Glasgow
ZIP/Postal Code
G12 0YN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
University College London Hospital
City
London
ZIP/Postal Code
N7 9NH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Royal Manchester Children?s Hospital
City
Manchester
ZIP/Postal Code
M13 9WL
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
The Christie NHS Foundation Trust
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Learn more about this trial

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

We'll reach out to this number within 24 hrs